Suppr超能文献

单核细胞增生李斯特菌将病毒抗原递送至I类加工和呈递途径。

Delivery of a viral antigen to the class I processing and presentation pathway by Listeria monocytogenes.

作者信息

Ikonomidis G, Paterson Y, Kos F J, Portnoy D A

机构信息

Department of Microbiology, University of Pennsylvania School of Medicine, Philadelphia 19104-6076.

出版信息

J Exp Med. 1994 Dec 1;180(6):2209-18. doi: 10.1084/jem.180.6.2209.

Abstract

Listeria monocytogenes is a facultative intracellular pathogen that grows in the cytoplasm of infected host cells. We examined the capacity of L. monocytogenes to introduce influenza nucleoprotein (NP) into the class I pathway of antigen presentation both in vitro and in vivo. Recombinant L. monocytogenes secreting a fusion of listeriolysin O and NP (LLO-NP) targeted infected cells for lysis by NP-specific class I-restricted cytotoxic T cells. Antigen presentation occurred in the context of three different class I haplotypes in vitro. A hemolysin-negative L. monocytogenes strain expressing LLO-NP was able to present in a class II-restricted manner. However, it failed to target infected cells for lysis by CD8+ T cells, indicating that hemolysin-dependent bacterial escape from the vacuole is necessary for class I presentation in vitro. Immunization of mice with a recombinant L. monocytogenes strain that stably expressed and secreted LLO-NP induced NP-specific CD8+ cytotoxic T lymphocytes. These studies have implications for the use of L. monocytogenes to deliver potentially any antigen to the class I pathway in vivo.

摘要

单核细胞增生李斯特菌是一种兼性细胞内病原体,可在受感染宿主细胞的细胞质中生长。我们在体外和体内研究了单核细胞增生李斯特菌将流感核蛋白(NP)引入I类抗原呈递途径的能力。分泌溶菌酶O和NP融合蛋白(LLO-NP)的重组单核细胞增生李斯特菌可被NP特异性I类限制性细胞毒性T细胞靶向裂解感染细胞。体外抗原呈递发生在三种不同的I类单倍型背景下。表达LLO-NP的溶血素阴性单核细胞增生李斯特菌菌株能够以II类限制性方式呈递抗原。然而,它不能被CD8+T细胞靶向裂解感染细胞,这表明溶血素依赖性细菌从液泡中逃逸对于体外I类呈递是必要的。用稳定表达和分泌LLO-NP的重组单核细胞增生李斯特菌菌株免疫小鼠可诱导NP特异性CD8+细胞毒性T淋巴细胞。这些研究对于利用单核细胞增生李斯特菌在体内将潜在的任何抗原递送至I类途径具有重要意义。

相似文献

引用本文的文献

2
Bacteria-Based Nanoprobes for Cancer Therapy.基于细菌的纳米探针用于癌症治疗。
Int J Nanomedicine. 2024 Jan 23;19:759-785. doi: 10.2147/IJN.S438164. eCollection 2024.
3
Engineering a dual vaccine against COVID-19 and tuberculosis.工程双疫苗以预防 COVID-19 和结核病。
Front Cell Infect Microbiol. 2023 Oct 26;13:1273019. doi: 10.3389/fcimb.2023.1273019. eCollection 2023.
4
: a promising vector for tumor immunotherapy.一种有前途的肿瘤免疫治疗载体。
Front Immunol. 2023 Oct 6;14:1278011. doi: 10.3389/fimmu.2023.1278011. eCollection 2023.
6
cancer vaccines: bridging innate and adaptive immunity.癌症疫苗:连接固有免疫和适应性免疫
Curr Clin Microbiol Rep. 2019 Dec;6(4):213-224. doi: 10.1007/s40588-019-00133-4. Epub 2019 Nov 20.
7
Advances in immunotherapy for cervical cancer.宫颈癌的免疫治疗进展。
Curr Opin Oncol. 2020 Sep;32(5):481-487. doi: 10.1097/CCO.0000000000000663.
10
Cancer immunotherapy: moving forward with peptide T cell vaccines.癌症免疫疗法:用肽 T 细胞疫苗推进。
Curr Opin Immunol. 2017 Aug;47:57-63. doi: 10.1016/j.coi.2017.07.003. Epub 2017 Jul 19.

本文引用的文献

1
Cellular resistance to infection.细胞抗感染能力。
J Exp Med. 1962 Sep 1;116(3):381-406. doi: 10.1084/jem.116.3.381.
4
Immunity to intracellular bacteria.对细胞内细菌的免疫
Annu Rev Immunol. 1993;11:129-63. doi: 10.1146/annurev.iy.11.040193.001021.
6
Cellular immunity to intracellular bacteria.针对胞内细菌的细胞免疫
Curr Opin Immunol. 1993 Aug;5(4):492-6. doi: 10.1016/0952-7915(93)90028-q.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验